Do Combination Therapies Hold Hope for Prostate Cancer Patients?
A phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
University of California San Francisco
Give to UCSFA phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
Laura Esserman discusses breast cancer risk factors, progress in the field and the importance of tailoring treatment for women with low-risk cancer while also identifying women at high risk of invasive cancer.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
UCSF researchers developed a new neighborhood-based model of care that brings medicine to people immediately after being diagnosed with hepatitis C.
A UCSF-led found that people who are experiencing homelessness have a 16-fold higher rate of sudden death from heart attacks, as well as other causes.
Being suspended from school or sent to the office is tied to a big drop in grade point average (GPA), especially for Black and Latinx children.
A study found that children who were recently diagnosed with type 1 diabetes need less supplemental insulin to keep their blood sugar in a healthy range if they use the immunotherapy drug teplizumab.
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.
Scientists found that the nervous system tamps down allergic response, which could change how asthma, Crohn’s and other inflammatory diseases are treated.
A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
UCSF's HS PROGRESS study aims to understand and treat Hidradenitis Suppurativa, an often debilitating condition disproportionately affecting women and people of color.